证券代码：002030 证券简称：达安基因 | --- | --- | --- | --- | --- | |-------------------------|---------------------------------------|-----------------------|--------------------------------------------------------|----------------| | | | | | 编号： 2021004 | | | √ 特定对象调研 | □ | 分析师会议 | | | | □ 媒体采访 | □ | 业绩说明会 | | | 投资者关系活动 类别 | □ 新闻发布会 | □ | 路演活动 | | | | □ 现场参观 | | | | | | □ 其他（） | | | | | 参与单位名称及 人员姓名 | 朱雀基金李扬 | 华泰资产王金成 | | | | 时间 | 2021-05-24 （下午 | 14:00-下午 15:30 ） | | | | | 地点 广州市高新技术开发区科学城香山路 | 19 | | 号（公司总部） | | 上市公司 ...

附件： 注：图右二为公司董事会秘书张斌与朱雀基金李扬先生、华泰资产王金成先生合影留念。 ...

附件： 注：图左四为公司董事会秘书张斌与中银证券黄彪、广东邦政资产熊政、中银证券周海涛、 珠海巨石资产李观生、中银证券熊永及丹松基金蒋昌志合影留念。 ...

证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|--------------------------------------------------------|----------------------------------------------|----------------------------------------------------------| | | | | 编号： 2022002 | | | √ 特定对象调研 | □ 分析师会议 | | | | □ 媒体采访 | □ 业绩说明会 | | | 投资者关系活动 类别 | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | □ 其他（） | | | | 参与单位名称及 | 中银证券周海涛、黄彪、熊永 熊政 珠海巨石资产李观生 | 丹松基金蒋昌志 | 广东邦政资产 | | 人员姓名 | | | | | 时间 2022-07-15 | （下午 14:30- | 下午 ...

证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 编号：2022003 | --- | --- | --- | --- | --- | |-----------------------|-------------------------------------------|--------------------------------------------------------|----------------------------|----------------| | | | | | | | | √ 特定对象调研 | □ 分析师会议 | | | | | □ 媒体采访 | □ 业绩说明会 | | | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | | | 类别 | □ 现场参观 | | | | | | □ 其他（） | | | | | 参与单位名称及 | 中信建投证券黄文欣、陈舒欣 何雯婧、高建翔 | 华美国际投资傅浩、李广生 | 深圳菁英时代廖泽略、朱可、 | 深圳高益资产余 | | 人员姓名 | 维念 | | | | | 时间 2022- ...

附件： 注：图左六为公司董事会秘书张斌与深圳高益资产余维念、深圳菁英时代朱可、深圳菁英时 代廖泽略、深圳菁英时代何雯婧、中信建投证券陈舒欣、中信建投证券黄文欣、华美国际投 资李广生、华美国际投资傅浩及深圳菁英时代高建翔合影留念。 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥2,659,768,271.81, representing a 23.46% increase year-over-year[5] - Net profit attributable to shareholders was ¥1,316,279,924.14, up 42.04% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥1,313,690,375.07, reflecting a 40.70% increase year-over-year[5] - Basic earnings per share for the period were ¥0.9379, a 42.04% increase year-over-year[5] - The company reported a comprehensive diluted earnings per share of ¥3.4991 based on the latest share capital[9] - The net profit for the period increased, leading to a 118.10% rise in income tax expenses to ¥951,386,510.73[21] - The net profit for the current period is 4,924,221,013.32 CNY, compared to 2,543,092,652.35 CNY in the previous period, representing an increase of approximately 93.5%[45] - The total revenue from operating activities reached 7,507,873,587.22 CNY, up from 4,933,555,068.47 CNY, indicating a growth of about 52.5% year-over-year[49] - The operating profit for the current period is 5,878,332,476.13 CNY, compared to 2,980,781,298.31 CNY in the previous period, reflecting an increase of approximately 97.5%[45] - The total comprehensive income for the current period is 4,927,148,591.01 CNY, compared to 2,542,869,045.49 CNY in the previous period, indicating an increase of about 93.5%[48] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥13,848,560,585.39, a 33.98% increase from the end of the previous year[8] - Shareholders' equity attributable to the parent company reached ¥10,843,973,419.93, marking a 47.51% increase compared to the previous year[8] - Total current assets reached RMB 8,310,729,983.48, up from RMB 5,984,980,388.61, indicating a growth of about 38.7%[33] - The company's total equity reached ¥11,155,577,160.70, up from ¥7,659,969,949.39, marking an increase of approximately 45.3%[39] - Total liabilities rose to ¥2,692,983,424.69 compared to ¥2,676,474,181.92, showing a slight increase of about 0.6%[39] - The current liabilities totaled ¥2,569,874,353.01, slightly up from ¥2,521,043,571.04, indicating an increase of approximately 1.4%[39] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥2,878,155,081.97, an increase of 32.41% compared to the same period last year[5] - The cash flow from operating activities generated a net amount of 2,878,155,081.97 CNY, compared to 2,173,722,019.97 CNY in the previous period, showing an increase of about 32.4%[52] - The cash inflow from investment activities totaled 1,551,671,841.27 CNY, compared to 1,762,453,217.57 CNY in the previous period, reflecting a decrease of about 11.9%[52] - The cash outflow for purchasing fixed assets and intangible assets was 1,021,454,509.91 CNY, compared to 265,257,798.79 CNY in the previous period, indicating a significant increase in capital expenditure[52] - The company did not report any net increase in borrowing from other financial institutions during the current period[52] Investments and R&D - R&D expenses rose by 59.11% to ¥431,499,051.61, indicating increased investment in innovation[18] - Investment income increased by 69.26% to ¥240,889,914.17, primarily due to the sale of a portion of equity in YunKang Group[21] - The company has plans for market expansion and new product development, as indicated by recent announcements regarding medical device certifications[30] Market and Operational Insights - Revenue for the first nine months of 2022 reached ¥9,335,814,909.05, a 65.61% increase compared to ¥5,637,145,611.28 in the same period of 2021, driven by sustained demand for COVID-19 testing kits and related equipment[18] - Operating costs increased by 67.29% to ¥2,385,604,623.18, reflecting higher sales volume[18] - The company has obtained multiple medical device registration certificates, enhancing its product portfolio and market presence[30] - The company’s undistributed profits grew by 72.53% to ¥7,975,816,837.58, reflecting accumulated operational gains[17] Foreign Exchange and Other Comprehensive Income - The company experienced a 478.55% increase in other comprehensive income, reaching ¥2,866,443.52, due to exchange rate fluctuations[17] - The company reported a foreign currency translation difference of 2,370,992.91 CNY, compared to -148,268.44 CNY in the previous period, showing a significant recovery[48] - The impact of exchange rate changes on cash and cash equivalents was $34.24 million, contrasting with a negative impact of $279.67 thousand previously[55] Audit and Reporting - The third quarter report was not audited[56]

Financial Performance - The company's operating revenue for the first half of 2022 reached ¥6,676,046,637.24, representing a 91.69% increase compared to ¥3,482,719,718.52 in the same period last year[34]. - Net profit attributable to shareholders was ¥3,594,563,598.70, a 124.96% increase from ¥1,597,875,201.73 year-on-year[34]. - The net cash flow from operating activities was ¥1,708,408,706.79, up 57.74% from ¥1,083,059,370.10 in the previous year[34]. - Basic earnings per share increased to ¥2.5612, a rise of 124.96% compared to ¥1.1385 in the same period last year[34]. - Total assets at the end of the reporting period were ¥13,127,721,702.37, reflecting a 27.00% increase from ¥10,336,444,131.31 at the end of the previous year[34]. - Net assets attributable to shareholders increased to ¥9,526,192,262.91, a 29.58% rise from ¥7,351,336,362.39 at the end of the previous year[34]. - The weighted average return on net assets was 40.45%, up from 31.53% in the previous year, indicating improved profitability[34]. - The total profit for the same period was CNY 4,336,264,611.28, reflecting a year-on-year increase of 133.51%[59]. - The company reported a net profit attributable to shareholders of the parent company of ¥3,594,563,598.70, a 124.96% increase from ¥1,597,875,201.73, due to ongoing demand for COVID-19 testing products[84]. Strategic Focus and Development - The company focuses on molecular diagnostic technology, integrating R&D, production, and sales of clinical testing reagents, instruments, and consumables[46]. - The strategic goal is to become a leading integrated supplier in the in vitro diagnostic industry, with a focus on clinical diagnostic technology and product development[46]. - The product lines cover infectious diseases, precision medicine, and public health, among others, continuously extending into the health sector[46]. - The company is actively involved in the development of automated testing systems, such as the DR-CL 2000 and LC-MS/MS systems, enhancing its laboratory capabilities[51]. - The company is focused on research and innovation, with an emphasis on new technologies and products to meet public health needs, particularly in the context of the COVID-19 pandemic[52]. - The company continues to enhance its independent innovation efforts, focusing on the development of molecular diagnostic technology and accelerating the implementation of immunology, POCT, and biochemical diagnostic platforms[62]. Market Position and Expansion - The company has expanded its market presence to over 140 countries and regions globally, enhancing its international market share[61]. - The company is positioned to benefit from the ongoing expansion of the healthcare sector, driven by national health policies and public health initiatives[52]. - The global IVD market is expected to maintain a growth rate of over 5%, driven by the rapid development of new technologies and the increasing concentration of the industry[53]. - The domestic IVD market is projected to grow at a rate of approximately 15% due to the ongoing medical reform and the shift from treatment to prevention[53]. - The company is leveraging strategic innovations and product upgrades to enhance its competitive position in the domestic IVD market[55]. - The company is positioned as a leader in the molecular diagnostics sector, with a strong brand presence and market leadership in various diagnostic fields[58]. Corporate Governance and Social Responsibility - The company has undergone a change in its controlling shareholder's name from "Guangzhou Zhongda Holdings Co., Ltd." to "Guangzhou Guangyong Technology Development Co., Ltd."[33]. - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[5]. - The company has established a performance and incentive system based on operational goals, significantly improving employee morale and work efficiency[65]. - The company actively participated in pandemic response efforts, deploying hundreds of employees across various departments to ensure production and supply continuity during the COVID-19 outbreak[63]. - The company has actively engaged in social responsibility activities, including donations to support public health initiatives and poverty alleviation efforts[67]. - The company made donations totaling RMB 1,000,600 for medical equipment to support COVID-19 prevention and control efforts in various regions[68]. Financial Management and Investments - The company has established a nationwide multi-level business platform, enhancing its sales capabilities in the diagnostic product market and accelerating international market expansion[78]. - The company reported a significant increase in accounts receivable, which rose by 83.67% to ¥4,150,224,912.30, reflecting the substantial increase in sales volume[84]. - The company has established a multi-level employee incentive mechanism to encourage innovation and entrepreneurship since 2014[119]. - The company has committed to optimizing its investment structure and enhancing the operational capabilities of its subsidiaries to support sustainable growth[66]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[155]. Environmental Initiatives - The company reduced carbon emissions by approximately 890,000 kilograms in the first half of 2022 through various energy-saving measures[125]. - The company has replaced approximately 800 energy-saving LED lights to promote energy efficiency[125]. - The company has committed to a paperless office initiative to reduce carbon footprint and promote low-carbon living[125]. Related Party Transactions - The company reported a total of 14,310.38 million yuan in sales to related parties, accounting for 2.14% of the total sales amount[151]. - The company engaged in related party transactions with a total value of 257.75 million yuan for purchasing goods, representing 0.15% of similar transactions[147]. - The company provided services to related parties amounting to 860.32 million yuan, which is 0.13% of the approved transaction amount[151]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 209,596, with significant holdings from state-owned entities[189]. - The largest shareholder, Guangzhou Guangyong Technology Development Co., Ltd., held 16.63% of shares, totaling 233,391,995[189]. - The company received cash dividends from its wholly-owned subsidiaries, indicating positive cash flow and shareholder returns[180].

Financial Performance - The company's operating revenue for Q1 2022 was ¥3,362,176,107.47, representing a 43.69% increase compared to ¥2,339,884,957.72 in the same period last year[6] - Net profit attributable to shareholders for Q1 2022 was ¥1,679,951,294.17, up 48.85% from ¥1,128,623,209.01 in the previous year[6] - The net profit after deducting non-recurring gains and losses was ¥1,667,947,149.90, reflecting a 49.86% increase from ¥1,112,981,665.53 year-on-year[6] - Basic earnings per share for Q1 2022 were ¥1.1970, an increase of 48.84% from ¥0.8042 in the previous year[6] - Total tax payable increased by 64.22% to ¥668,415,715.48, attributed to higher operating revenue[18] - The total comprehensive income for the current period was ¥1,690,303,553.03, compared to ¥1,134,776,587.05 in the previous period, reflecting a growth of about 49.0%[46] Cash Flow - The net cash flow from operating activities was ¥839,383,630.81, which is a 21.29% increase compared to ¥692,043,744.56 in the same period last year[6] - Operating cash flow generated from operating activities amounted to ¥839,383,630.81, an increase of 21.3% compared to ¥692,043,744.56 in the previous period[49] - Cash inflow from investment activities totaled ¥523,980,893.91, a decrease of 42.0% from ¥903,192,865.94 in the previous period[51] - Net cash flow from financing activities was -¥26,494,506.77, compared to -¥133,731,670.65 in the previous period, indicating an improvement[51] - Total cash outflow from operating activities was ¥2,132,451,712.30, an increase of 73.3% from ¥1,230,421,124.68 in the previous period[49] Assets and Liabilities - Total assets at the end of Q1 2022 reached ¥12,559,021,215.95, marking a 21.50% increase from ¥10,336,444,131.31 at the end of the previous year[6] - The company's total current assets amounted to CNY 7,601,347,585.97, up from CNY 5,984,980,388.61, indicating an increase of about 27%[32] - The total liabilities of the company were CNY 3,208,747,814.37, up from CNY 2,676,474,181.92, which is an increase of approximately 19.8%[36] - The company's equity attributable to shareholders was ¥9,031,388,111.14, which is a 22.85% increase from the previous year[9] Operational Metrics - Accounts receivable increased by 49.30% to ¥3,373,712,388.85 from ¥2,259,665,605.15 year-on-year, driven by increased operating revenue[15] - The company reported a 30.81% increase in prepayments, totaling ¥238,842,094.33 compared to ¥182,589,388.68 in the previous year, due to increased business volume[15] - Accounts payable rose by 48.26% to ¥819,884,449.27 from ¥553,009,648.58, reflecting increased business activity[15] - Cash received from the sale of goods and services was ¥2,553,446,552.78, compared to ¥1,727,739,339.40 in the previous period, reflecting a growth of 47.8%[49] Research and Development - Research and development expenses surged by 97.46% to ¥119,790,428.09, indicating a stronger focus on innovation[18] - Research and development expenses rose to ¥119,790,428.09 from ¥60,666,828.78, indicating an increase of approximately 97.2%[43] Other Financial Metrics - The company reported a credit impairment loss of -¥51,276,230.93, a 157.54% increase, linked to higher revenue[18] - Other income decreased by 54.35% to ¥11,061,853.30, primarily due to reduced government subsidies compared to the previous year[18] - The company has no asset impairment losses reported during the period, marking a 100% decrease from the previous year[18] - The company reported a net investment income of ¥63,160,614.43, up from ¥52,057,966.18, indicating an increase of approximately 21.4%[43] Future Outlook - The company plans to continue expanding its business operations and exploring new strategies for growth in the upcoming quarters[30] - The company has obtained a medical device registration certificate, indicating progress in new product development[30]

Financial Performance - The company's operating revenue for 2021 reached ¥7,664,262,202.27, representing a 43.49% increase compared to ¥5,341,209,627.83 in 2020 [28]. - Net profit attributable to shareholders for 2021 was ¥3,618,186,564.12, a 47.74% increase from ¥2,449,090,154.35 in 2020 [28]. - The net profit after deducting non-recurring gains and losses was ¥3,537,112,727.59, up 49.41% from ¥2,367,365,192.11 in 2020 [28]. - The net cash flow from operating activities for 2021 was ¥3,304,545,784.75, an increase of 31.42% compared to ¥2,514,511,529.56 in 2020 [28]. - Basic earnings per share for 2021 were ¥2.5781, reflecting a 47.73% increase from ¥1.7451 in 2020 [28]. - Total assets at the end of 2021 amounted to ¥10,336,444,131.31, a 54.27% increase from ¥6,700,027,768.66 at the end of 2020 [28]. - Net assets attributable to shareholders reached ¥7,351,336,362.39, up 72.22% from ¥4,268,624,949.35 at the end of 2020 [28]. - The total profit reached ¥4,120,081,464.63, marking a 41.93% increase year-over-year, while the net profit attributable to shareholders was ¥3,618,186,564.12, up by 47.74% [61]. - The company reported a net income of ¥81,073,836.53, demonstrating stable financial performance amidst market fluctuations [37]. Market and Industry Trends - The IVD market is expected to grow at a rate of over 5% globally, driven by advancements in diagnostic technology and increased health awareness [42]. - The domestic IVD market is projected to grow at approximately 15%, fueled by the ongoing medical reform and the impact of the COVID-19 pandemic [43]. - The overall industry is experiencing a trend towards consolidation, with an increasing concentration of traditional diagnostic technology platforms [43]. - The company anticipates that the demand for personalized testing in areas such as oncology and genetic diseases will create substantial growth opportunities in molecular diagnostics [45]. Research and Development - The company focuses on the research and development of clinical diagnostic technologies and products, aiming to become a top-tier supplier in the in vitro diagnostics industry [48]. - The company has developed a comprehensive product line that addresses infectious diseases, prenatal care, precision medicine, and public health, among others [48]. - The company has made significant advancements in high-sensitivity detection systems for diseases, including a new integrated detection system for hepatitis C [96]. - The company achieved a significant increase in R&D investment, totaling approximately ¥631.77 million in 2021, up 166.32% from ¥237.22 million in 2020 [99]. - R&D expenditure accounted for 8.24% of total revenue in 2021, compared to 4.44% in 2020, reflecting a 3.80% increase [99]. - The number of R&D personnel rose to 790 in 2021, a 156.49% increase from 308 in 2020, although their proportion of total employees decreased by 4.03% [98]. Product Development and Offerings - The product portfolio includes a wide range of diagnostic kits, such as the 2019-nCoV nucleic acid test kits and various hepatitis virus detection kits, covering multiple disease areas [49]. - The company has developed a series of diagnostic reagents for acute infectious diseases, aiming to enhance market competitiveness and diagnostic efficiency [95]. - New product launches included a series of advanced diagnostic kits, contributing to a 30% increase in product sales [180]. - The company plans to enhance its R&D capabilities by building a "wall-less" research institute and accelerating the development of integrated product lines including core raw materials, diagnostic reagents, consumables, and specialized equipment [125]. Strategic Focus and Expansion - The strategic focus on expanding into new markets and enhancing product offerings is expected to drive future revenue growth [42]. - The company is focused on expanding its market presence and exploring potential mergers and acquisitions to strengthen its competitive edge [48]. - The company plans to enhance its market presence in Southeast Asia, targeting a 10% market share by 2023 [172]. - A strategic acquisition of a biotechnology firm is in progress, aimed at enhancing research capabilities and product offerings [172]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of 500 million RMB allocated for this purpose [180]. Corporate Governance and Management - The company emphasizes the importance of maintaining a robust governance structure in compliance with relevant laws and regulations [145]. - The company has established a comprehensive investor relations management section on its website to ensure transparent information disclosure and communication with investors [152]. - The company has a complete and independent financial accounting system, with separate financial departments and bank accounts from its controlling shareholder [160]. - The company has a diverse board with members holding various positions in other companies, indicating a broad network [186]. - The company has implemented a structured decision-making process for determining executive compensation [187]. Social Responsibility and Community Engagement - The company actively participated in social responsibility initiatives, providing technical support for nucleic acid testing and donating a total of ¥1,000,000 to various charitable causes throughout the year [71]. - The company donated a total of RMB 3,000,000 to various educational and healthcare initiatives in 2021 [72][73][74]. - The company purchased poverty alleviation products worth RMB 443,190 to support local farmers [73]. Future Outlook and Guidance - The company has outlined performance guidance for the next fiscal year, expecting continued growth [169]. - The company plans to enhance its product market coverage and sales scale while maintaining good product profitability [134]. - The company reported a revenue guidance for 2022, projecting a growth rate of 25% year-on-year, aiming for 1.875 billion RMB [182].